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milder than the 1996 outbreak, with
less illness and death; most patients
had uncomplicated dengue fever, and
only a few had DHF/DSS. Of the 874
serum samples that we tested, 456
(52.3%) were positive for dengue-
specific immunoglobulin M antibod-
ies by enzyme-linked immunosorbent
assay (Panbio, Sinnamon Park,
Queensland, Australia), and more
than one third of these were from
patients in the 21- to 30-year age
group (8).
Dengue virus types 1, 2, and 3
have all been isolated during previous
dengue outbreaks in Delhi, but a par-
ticular type has always predominated.
During the 1996 outbreak of
DHF/DSS, we had 26 isolates of
dengue virus type 2, but only 1 isolate
was identified as dengue type 1 (5).
However, we subsequently showed
that dengue virus type 1 continued to
circulate during the postepidemic
period and became the predominant
strain (9). Dengue virus type 3 has
recently reemerged in South Asia,
including north India (10). We now
report this culture-confirmed outbreak
of dengue from Delhi, during which
the simultaneous transmission of all 4
dengue virus types has been demon-
strated for the first time in India, with
no particular type predominating.
This finding suggests that dengue is
now truly endemic in this region.
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Borrelia burgdorferi
and Anaplasma
phagocytophilum
Coinfection 
To the Editor: In central Europe,
Anaplasma phagocytophilum and
Borrelia burgdorferi are transmitted
by the hard tick Ixodes ricinus (1).
Acute human granulocytic ehrlichio-
sis (HGE) caused by A. phagocy-
tophilum has rarely been documented
in Europe (2). Typical symptoms
include fever, headache, myalgia,
leukopenia, thrombocytopenia, and
abnormal liver function test results.
The serologic prevalence ranges from
1.9% to 14% in Germany (1), while
clinically apparent infections of HGE
have not been reported. 
Acute Lyme borreliosis in Europe
is associated with erythema migrans
(3), recognized in up to 90% of
patients (4). Erythema migrans may
be accompanied by systemic symp-
toms such as fever, fatigue, myalgia,
arthralgia, headache, or stiff neck
(3,4). In southern Germany, an inci-
dence of 111 per 100,000 inhabitants
has been reported (4).
A 60-year-old woman from north-
ern Germany was admitted with tem-
perature of <40°C, headache, myal-
gia, and generalized weakness that
had begun 6 days earlier. She had
noticed an erythema migrans on her
right thigh 4 days before she sought
treatment. At admission, a tender,
5 × 8 cm rash and a central papule
were seen, but without central clear-
ing. The clinical examination was oth-
erwise normal. Three weeks earlier
she had been on a trekking tour in
Austria and Slovenia but had not been
aware of any tick bites. 
The leukocyte count was 3,030/µL
(normal 4,000–9,000), with 65% neu-
trophils, 24% lymphocytes, 10%
monocytes, and 1% lymphoid cells.
The following results were observed:
platelets 127,000/µL(normal 150,000–
450,000), aspartate aminotransferase
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108 U/L(normal <31), alanine amino-
transferase 154 U/L (normal <34),
gamma-glutamyl transferase 98 U/L
(normal <38), lactate dehydrogenase
317 U/L (normal <247), alkaline
phosphatase 314 U/L (normal <237),
direct bilirubin 4.7 µmol/L (normal
<3.4), C-reactive protein 132 mg/L
(normal <5), and neopterin 30 nmol/L
(normal <10). All other routine labo-
ratory parameters were normal.
May-Grünwald-Giemsa (Fluke,
Neu Ulm, Germany)–stained whole-
blood smears did not show
Anaplasma initially and during fol-
low-up. On admission serum antibody
tests were negative for A. phagocy-
tophilum, B. burgdorferi, hepatitis A,
B, and C, human herpes virus 6, her-
pes simplex virus 1 and 2, Epstein-
Barr virus, cytomegalovirus, and tick-
borne encephalitis virus. Because
Lyme borreliosis and possible HGE
were suspected, the patient was treat-
ed with oral doxycycline 200 mg once
daily for 3 weeks. Within 4 days after
initiation of treatment, the patient
recovered completely; thrombocytes
and leukocytes had normalized. Liver
enzyme levels were still elevated but
had normalized at a follow-up exami-
nation 28 days later.
Four days after the initial examina-
tion, results for Borrelia-specific
immunoglobulin M (IgM) antibodies
were positive, while results for IgG
antibodies remained negative (Table).
Four weeks after the onset of symp-
toms, a test for A. phagocytophilum–
specific IgM antibodies was positive
and IgG was negative thereafter
(Table). An initial EDTA blood sam-
ple that was stored frozen and exam-
ined retrospectively as well as follow-
up EDTA blood samples were nega-
tive for A. phagocytophilum in a poly-
merase chain reaction (PCR) assay. 
One year after initial examination,
results for Borrelia-specific IgM anti-
bodies were positive and results for A.
phagocytophilum-specific antibodies
were negative (Table). Although HGE
has not been reported in Germany, a
coinfection with B. burgdorferi and A.
phagocytophilum  should be consid-
ered in patients with erythema
migrans and atypical changes for
Lyme borreliosis such as fever,
leukopenia, thrombocytopenia, and
elevated liver function test results.
The patient had traveled to an area
where both tickborne pathogens, A.
phagocytophilum and B. burgdorferi,
were endemic. Erythema migrans and
antibody follow up suggested Lyme
borreliosis. High fever, leukopenia,
thrombocytopenia, and elevated liver
enzyme levels indicated HGE.
Anaplasma PCR was negative, possi-
bly because blood samples were test-
ed retrospectively after 3 months of
storage at –20°C. However, a com-
mercially available indirect fluores-
cent antibody assay was able to
demonstrate seroconversion of HGE-
specific IgM antibodies 1 month after
the initial onset of symptoms.
According to manufacturer’s informa-
tion, specificity ranged from 97.5% to
100%; sensitivity was 71.4% at 60
days after A. phagocytophilum infec-
tion. A. phagocytophilum IgG anti-
bodies were not detected during fol-
low-up, likely because of prompt
treatment with doxycycline.
Wormser et al. (5) suggested that
Borrelia-specific antibodies might
indicate false-positive results in
patients with HGE infection. Our
case, however, meets criteria of a
newly acquired infection with B.
burgdorferi sensu lato, with an ery-
thema migrans and seroconversion of
Borrelia-specific IgM antibodies.
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Corynebacterium
pseudogenitalium
Urinary Tract
Infection
To the Editor: A 64-year-old man
was admitted to the urology depart-
ment of Cochin Hospital in Paris,
France, for acute urinary retention. He
had a history of recurrent urolithiasis
and undocumented urinary tract
symptoms. At admission, a urethral
catheter was inserted, and a plain radi-
ograph showed 2 bladder stones and
milk of calcium calcifications. Three
days later, he underwent extracorpo-
real shock wave lithotripsy treatment,
and empiric antimicrobial drug thera-
py with intravenous ceftriaxone, 1
g/day for 3 days, was administered.
Three consecutive urinalyses showed
a pH of 9, crystals of struvite, hema-
turia, and 105 leukocytes/mL. Gram-
positive rods with rounded ends and
nonparallel sides, arranged in pal-
isades or in V shapes, were observed,
which suggested the presence of
corynebacteria. Urine cultures were
positive and yielded a pure culture of
105 CFU/mLof Corynebacterium spp. 
The isolated strain showed slight
growth after 24 or 48 h of incubation
on horse blood agar medium but
abundant growth on the same medium
containing 1% Tween 80 under aero-
bic conditions (5% CO2). Colonies
were white, opaque, smooth, convex,
and nonhemolytic. This lipid-requir-
ing strain was catalase positive and
strongly urease positive. Testing with
the API-Coryne strip (bioMérieux,
Marcy l’Etoile, France) showed that
the strain was nitrate-reduction posi-
tive and produced acid from glucose,
ribose, sucrose, and maltose.
However, this strain, which was des-
ignated CCH052683, did not
hydrolyze gelatin or esculin. It was
identified as Corynebacterium group
F1 (the corresponding numeric profile
of the gallery API-Coryne was
3001325).
The strain was correctly identified
to the species level as Corynebac-
terium pseudogenitalium by using
polymerase chain reaction and
sequencing 16 rRNA as previously
described (1,2). Comparison of 785
nucleotides (546–1,331) gave a 16S
rDNA similarity value of 99.9%
between the sequences of the isolated
strain and C. pseudogenitaliumATCC
33039/NCTC11860 (European Mole-
cular Biology Laboratory accession
no. X81872).
The strain was sensitive to peni-
cillin, ampicillin, gentamicin, rifam-
pin, vancomycin, teicoplanin, tetracy-
cline, sulfamethoxazole, trimetho-
prim, fusidic acid, ciprofloxacin, and
norfloxacin and resistant to erythro-
mycin, lincomycin, and nitrofuran-
toin. Ceftriaxone was replaced by nor-
floxacin (400 mg twice a day) for 1
month. The patient improved and
remained healthy 6 months after ther-
apy. 
Nondiphtheric corynebacteria are
of increasing importance. They have
been observed in human specimens,
and many new taxa of coryneform
bacteria have been described (3).
Interest in their taxonomy is increas-
ing, and molecular, phenotypic, and
biochemical analyses have resulted in
the reclassification of this genus (3).
C. pseudogenitalium was described in
1979 by Furness et al. (4) for
lipophilic corynebacteria isolated
from urinary tract and was not consid-
ered a pathogen, in contrast to C. gen-
italium. However, these 2 species
were not included in the official list of
recognized species. 
C. pseudogenitalium was divided
into 5 types based on biochemical pat-
terns, and strains of the type C-5 were
differentiated from other types on the
basis of urease production. The bio-
chemical and physiologic characteris-
tics of this C-5 type were similar of
those of the coryneform group F-1
described by the Centers for Disease
Control and Prevention (CDC). In
1995, a comprehensive study on
lipophilic corynebacteria demonstrat-
ed by DNA-DNA hybridization the
similarity between a reference strain
of C. pseudogenitalium type C-5 and
reference strains of the CDC coryne-
form group F-1 (1). The CDC group
F-1 make up 2 genomic groups at the
species level. As shown by 16S rDNA
gene comparisons, isolate CCH0-
52683 belongs to the genomic group,
including a reference strain of C.
pseudogenitalium type C-5 ATCC
33039 (CCUG 27540, sequence
X81872) and a reference strain of
CDC group F-1 (CDC G4330,
sequence X81905) (Figure). The other
genomic group of CDC group F-1 is
represented by strain CDC G5911
(sequence X81904). The molecular
genetic investigations identified our
isolate as C. pseudogenitalium and
placed it in 1 of the 2 genomic groups
of CDC group F-1, which cannot be
differentiated by biochemical tests
(1). 
The pathogenicity of this bacteri-
um was associated with strong urease
activity. This activity is similar to that
of other urease-positive microorgan-
isms, such as C. urealyticum and
Proteus spp. (5,6), which infect the
urinary tract. Unfortunately, the blad-
der stones were not analyzed after
extracorporeal shock wave lithotripsy
treatment. The C.  pseudogenitalium
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